Cargando…

Towards a unified protocol for handling of CSF before β-amyloid measurements

BACKGROUND: Widespread implementation of Alzheimer’s disease biomarkers in routine clinical practice requires the establishment of standard operating procedures for pre-analytical handling of cerebrospinal fluid (CSF). METHODS: Here, CSF collection and storage protocols were optimized for measuremen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Janelidze, Shorena, Stomrud, Erik, Brix, Britta, Hansson, Oskar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6642586/ https://www.ncbi.nlm.nih.gov/pubmed/31324260 http://dx.doi.org/10.1186/s13195-019-0517-9

Ejemplares similares

β-Amyloid–Dependent and –Independent Genetic Pathways Regulating CSF Tau Biomarkers in Alzheimer Disease
por: Kumar, Atul, et al.
Publicado: (2022)

Association of CSF Aβ(38) Levels With Risk of Alzheimer Disease–Related Decline
por: Cullen, Nicholas, et al.
Publicado: (2022)

Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer’s disease
por: Cullen, Nicholas C, et al.
Publicado: (2023)

CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease
por: Janelidze, Shorena, et al.
Publicado: (2018)

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
por: Palmqvist, Sebastian, et al.
Publicado: (2019)

CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease
por: Janelidze, Shorena, et al.
Publicado: (2016)

Associations of CSF PDGFRβ With Aging, Blood-Brain Barrier Damage, Neuroinflammation, and Alzheimer Disease Pathologic Changes
por: Cicognola, Claudia, et al.
Publicado: (2023)

Associations Between CSF Markers of Inflammation, White Matter Lesions, and Cognitive Decline in Individuals Without Dementia
por: Gertje, Eske Christiane, et al.
Publicado: (2023)

Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status
por: Palmqvist, Sebastian, et al.
Publicado: (2019)

Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer’s disease
por: Pereira, Joana B, et al.
Publicado: (2020)

Plasma β-amyloid in Alzheimer’s disease and vascular disease
por: Janelidze, Shorena, et al.
Publicado: (2016)

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease
por: Pereira, Joana B, et al.
Publicado: (2021)

Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects
por: Pereira, Joana B, et al.
Publicado: (2021)

Accurate risk estimation of β-amyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms
por: Palmqvist, Sebastian, et al.
Publicado: (2019)

Optimized Standard Operating Procedures for the Analysis of Cerebrospinal Fluid Aβ(42) and the Ratios of Aβ Isoforms Using Low Protein Binding Tubes
por: Vanderstichele, Hugo Marcel Johan, et al.
Publicado: (2016)

Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays
por: Leuzy, Antoine, et al.
Publicado: (2021)

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
por: Mattsson‐Carlgren, Niklas, et al.
Publicado: (2021)

Plasma Phospho‐Tau Identifies Alzheimer's Co‐Pathology in Patients with Lewy Body Disease
por: Hall, Sara, et al.
Publicado: (2020)

CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease
por: Barthélemy, Nicolas R., et al.
Publicado: (2023)

Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s disease
por: Whelan, Christopher D., et al.
Publicado: (2019)

The implications of different approaches to define AT(N) in Alzheimer disease
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2020)

Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers
por: Ossenkoppele, Rik, et al.
Publicado: (2021)

Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer’s disease
por: Andersson, Emelie, et al.
Publicado: (2020)

Pre‐analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF
por: Hansson, Oskar, et al.
Publicado: (2020)

Levels of islet amyloid polypeptide in cerebrospinal fluid and plasma from patients with Alzheimer’s disease
por: Schultz, Nina, et al.
Publicado: (2019)

Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals
por: Groot, Colin, et al.
Publicado: (2022)

Derivation and utility of an Aβ-PET pathology accumulation index to estimate Aβ load
por: Leuzy, Antoine, et al.
Publicado: (2020)

Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease
por: Pichet Binette, Alexa, et al.
Publicado: (2022)

Association of β-Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition
por: Tideman, Pontus, et al.
Publicado: (2022)

β-amyloid pathology and hippocampal atrophy are independently associated with memory function in cognitively healthy elderly
por: Svenningsson, Anna L., et al.
Publicado: (2019)

Measures of cortical microstructure are linked to amyloid pathology in Alzheimer’s disease
por: Spotorno, Nicola, et al.
Publicado: (2022)

CSF placental growth factor – a novel candidate biomarker of frontotemporal dementia
por: Hansson, Oskar, et al.
Publicado: (2019)

Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations
por: Cullen, Nicholas C., et al.
Publicado: (2021)

DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease
por: Pereira, Joana B., et al.
Publicado: (2023)

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
por: Hansson, Oskar, et al.
Publicado: (2019)

A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases
por: Brum, Wagner S., et al.
Publicado: (2023)

Cerebral white matter lesions – associations with Aβ isoforms and amyloid PET
por: van Westen, Danielle, et al.
Publicado: (2016)

Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1–42)/Aβ(1–40)
por: Vanderstichele, Hugo, et al.
Publicado: (2017)

Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease
por: Janelidze, Shorena, et al.
Publicado: (2020)

Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer’s disease pathology
por: Pereira, Joana B., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p9tnad9p7bdoaton81o0m3u1ug